<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193098</url>
  </required_header>
  <id_info>
    <org_study_id>E2019090A</org_study_id>
    <nct_id>NCT04193098</nct_id>
  </id_info>
  <brief_title>Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC</brief_title>
  <official_title>Phase I Clinical Study of Autologous Cytotoxic T Lymphocyte (CTL) Cell Immunotherapy Combination With PD-1 Inhibitor in the Second-line Treatment of Stage IIIB/IIIC/IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, unicentric, open-labe phase I study is to evaluate the safety and effect of&#xD;
      autologous cytotoxic T lymphocyte immunotherapy combination with PD-1 inhibitor in the&#xD;
      second-line treatment of stage IIIB/IIIC/IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the stage IIIB/IIIC/IV NSCLC, patients received Toripalimab Injection (PD-1 inhibitor)&#xD;
      240mg, d1; CTL cells venous re-transfusion &gt;=1x10^9, d14; Q3W; till disease progresion, or&#xD;
      intolerable adverse reactions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>ORR was calculated by the percentage of patients with a confirmed complete (CR) or partial response (PR).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Second-line Treatment</condition>
  <arm_group>
    <arm_group_label>Arm: CTL plus PD-1 inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTL , Toripalimab Toripalimab intravenous infusion 240mg d1; CTL, 1x10^9, intravenous infusion,d14; Q3W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTL</intervention_name>
    <description>CTL injection</description>
    <arm_group_label>Arm: CTL plus PD-1 inhibitor</arm_group_label>
    <other_name>Autologous cytotoxic T lymphocyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Toripalimab injection</description>
    <arm_group_label>Arm: CTL plus PD-1 inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who must meet all the following criteria should be selected:&#xD;
&#xD;
          1. Agreeing to participate in this study and signing a written informed consent.&#xD;
&#xD;
          2. Male or female,from 18 to 75 years (including 18 and 75 years).&#xD;
&#xD;
          3. The life expectancy will be longer than 3 months and can be followed up.&#xD;
&#xD;
          4. Patients with stage IIIB/IIIC/IV NSCLC were confirmed by histological /cytological and&#xD;
             imaging examinations. According to RECIST 1.1 standard, there will be at least one&#xD;
             measurable lesion.&#xD;
&#xD;
          5. Initial medical treatment.Patients with adenocarcinoma need wild type of EGFR gene and&#xD;
             ALK fusion gene negative to be included in this study.&#xD;
&#xD;
          6. ECOG score will be 0 or 1 within 7 days before randomization.&#xD;
&#xD;
          7. Within 14 days before the start of treatment, the results of laboratory test of blood&#xD;
             routine, liver, kidney function and hormone levels must be met the following criteria:&#xD;
&#xD;
             White blood cells: more than 3.0 × 109/L; Platelets: more than 100 × 109/L;&#xD;
             Neutrophils: more than 1.5 × 109/L; Hemoglobin: more than 80g/L; Serum glutamate&#xD;
             pyruvate transaminase: less than 2.5 folds of the upper normal limit (ULN); Serum&#xD;
             glutamic-oxal (o) acetic transaminase: less than 2.5 × ULN; Serum bilirubin: less than&#xD;
             1.25 × ULN; Serum creatinine: less than 1.25 × ULN. Cortisol and thyroid function will&#xD;
             be in the normal range.&#xD;
&#xD;
          8. The toxicity and side effects of previous chemotherapy will must be alleviated to&#xD;
             grade 1 or below (except hair loss).&#xD;
&#xD;
          9. Female subjects must take effective contraceptive measures throughout the study&#xD;
             period; serum or urine pregnancy test results must be negative during screening and&#xD;
             the whole study period.&#xD;
&#xD;
         10. Male subjects should take effective contraceptive measures from the beginning of&#xD;
             treatment to within 6 months after the end of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria could not participate in this study:&#xD;
&#xD;
          1. Adenocarcinoma subjects with EGFR sensitive mutation or ALK translocation; molecular&#xD;
             detection of EGFR-sensitive mutations or ALK translocations is not required in&#xD;
             squamous carcinoma patients.&#xD;
&#xD;
          2. NSCLC that had received chemotherapy in the past.&#xD;
&#xD;
          3. Other malignant tumors needed treatment within five years.&#xD;
&#xD;
          4. Allogeneic tissue/organ transplantation.&#xD;
&#xD;
          5. Participating in research drug therapy within 4 weeks before the first administration&#xD;
             of the trial.&#xD;
&#xD;
          6. Systemic glucocorticoid therapy or any other form of immunosuppressive therapy (except&#xD;
             glucocorticoid preconditioned with docetaxel) is being administered within 3 days&#xD;
             before the first administration of the experimental therapy.&#xD;
&#xD;
          7. Received anti-tumor monoclonal antibody (mAb), chemotherapy, targeted small molecule&#xD;
             therapy or major surgery within 4 weeks before the first use of the drug; received&#xD;
             chest radiotherapy greater than 30 Gy within 6 months before the first use of the&#xD;
             drug; and received chest radiotherapy with 30 Gy or less within 1 month before the&#xD;
             first use of the drug.&#xD;
&#xD;
          8. Previous treatment with PD-1/PD-L1 antibodies.&#xD;
&#xD;
          9. Over the past two years, patients with active autoimmune diseases requiring systemic&#xD;
             treatment, such as the use of corticosteroids, or immunosuppressants. Substitution&#xD;
             therapy (such as thyroxine, insulin, or physiological corticosteroid replacement&#xD;
             therapy for adrenal or pituitary dysfunction) is not a systemic treatment.&#xD;
&#xD;
         10. Patients with congenital or acquired immunodeficiency (e.g. HIV-infected persons),&#xD;
             active hepatitis B (HBV-DNA &gt; 10^3 copies/ml) or hepatitis C (hepatitis C antibody&#xD;
             positive), and HCV-RNA higher than the detection limit of the analytical method.&#xD;
&#xD;
         11. Subjects with active central nervous system (CNS) metastases and/or cancerous&#xD;
             meningitis.&#xD;
&#xD;
         12. Patients with active infections requiring systemic intravenous therapy. Mental illness&#xD;
             or other illnesses, such as uncontrollable heart disease or pulmonary disease,&#xD;
             diabetes, etc.&#xD;
&#xD;
         13. Subjects who are known to be allergic to any of the constituents of the drug being&#xD;
             studied.&#xD;
&#xD;
         14. Subjects with a recent history of drug abuse (including alcohol) within one year.&#xD;
&#xD;
         15. Compliance is poor and can not cooperate with clinical research.&#xD;
&#xD;
         16. Female subjects who are pregnant or breastfeeding, or who are expected to be pregnant&#xD;
             during the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiubao Ren, M.D, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiubao Ren, M.D, Ph.D</last_name>
    <phone>86-22-23340123</phone>
    <phone_ext>3173</phone_ext>
    <email>renxiubao@tjmuch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Liu, M.D, Ph.D</last_name>
    <phone>86-15900243633</phone>
    <email>liangcoh@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Liu, MD. Ph.D</last_name>
      <phone>86-22-23340123</phone>
      <phone_ext>3172</phone_ext>
      <email>liangcoh@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiubao Ren, MD. PhD.</last_name>
      <phone>86-22-23340123</phone>
      <phone_ext>3173</phone_ext>
      <email>renxiubao@tjmuch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Sun, Ph.D</last_name>
      <phone>86-22-23340123-6322</phone>
      <email>sunqian923@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>July 5, 2020</last_update_submitted>
  <last_update_submitted_qc>July 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

